OncoSec Medical Inc (ONCSQ)

[mybikeisorange]

Here is what the collaboration with ADXS looks like. Notice how in the first paragraph ADXS mentions the "collaboration agreement", plus the quotes from Merck. There is no agreement between ONCS and Merck.

Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration agreement with Merck, known as MSD outside the United States and Canada, through its subsidiaries, to evaluate the combination of Advaxis's Lm-LLO cancer immunotherapy, ADXS-PSA, with Merck's investigational anti PD-1 antibody, pembrolizumab.

And the quote from Merck:

"Collaborations such as this are an integral part of Merck's strategy to evaluate the potential of pembrolizumab in multiple combinations for a broad range of cancers," said Dr. Eric Rubin, vice president Oncology, Merck Research Laboratories. "We look forward to working with Advaxis to evaluate this novel investigational combination immunotherapy for the treatment of advanced prostate cancer."